



ImaBiotech signs license agreement with Lawrence Berkeley National Laboratory

Lille, France and Berkeley, California, USA – 14th April, 2016 – ImaBiotech, a CRO company developing and offering mass spectrometry imaging (MSI) services, applications, and software, announces today a license agreement with Lawrence Berkeley National Laboratory (Berkeley Lab) to “OpenMSI” intellectual property to support ImaBiotech Multimaging™ technology.

ImaBiotech’s Multimaging™ technology accelerates drug pharmacokinetic, pharmacology, toxicology, and formulation evaluation. Multimaging™ allows for the combination and overlay of different image files acquired from different imaging techniques (quantitative MALDI imaging, staining, and immune-staining) to provide confidence in the data sets. This platform has the advantage to quantitatively study the distribution of analytes at a cellular level. It can be used from drug discovery through clinical development, resulting in a better and faster drug selection.

Berkeley Lab’s OpenMSI software leverages Big Data resources to provide the most advanced web-based tool for analyzing, visualizing, managing and sharing MSI data in real time to enable advanced biotechnology solutions such as improved disease diagnostics or more effective therapeutics. This innovative approach provides a global structure for all types of MSI images and data files to be instantaneously and securely shared over a cloud-based system, with access anywhere around the world.

“Our license agreement with Berkeley Lab strengthens ImaBiotech’s leadership in quantitative MSI analysis,” said Jonathan Stauber, Chief Executive Officer of ImaBiotech. “Thanks to this license agreement, ImaBiotech will continue to improve and develop new services to support our customers’ needs. We are very proud to sign a license agreement with one of the most prestigious research laboratories in the world.”

“Lab-industry partnerships, such as ImaBiotech’s licensing of Berkeley Lab’s OpenMSI intellectual property, are vital to transitioning new innovations into the marketplace,” said Elsie Quaite-Randall, Berkeley Lab’s Chief Technology Transfer Officer. ImaBiotech’s foundation in MSI research and its multi-million dollar investment in bioanalysis equipment indicate that OpenMSI intellectual property can be quickly and naturally integrated into the company’s evaluation services and platform.

About ImaBiotech

ImaBiotech is a contract research organization (CRO) that offers services in mass spectrometry imaging (MSI); along with developing and implementing new imaging technologies, such as Quantinetix™ and Multimaging™. The main facility is located in Europe (Lille, France), with an office in North America (Cambridge, MA) and a distributor in Asia (Tokyo, Japan). In order to accelerate drug development, ImaBiotech offers Mass Spectrometry Services, such as MALDI high resolution mass spectrometry imaging to provide a cost effective solution to preclinical and clinical studies. This molecular technique is used both qualitatively and quantitatively for understanding the efficacy and toxicity of drug candidates.

About Berkeley Lab

Lawrence Berkeley National Laboratory (Berkeley Lab), www.lbl.gov, delivers science solutions to the world – solutions derived from the hundreds of patented and patent pending inventions plus copyrighted software in the Lab’s portfolio as well as scores of peer-reviewed manuscripts published each year in premier scientific publications. The University of California manages Berkeley Lab for the U.S. Department of Energy’s Office of Science, the single largest supporter of basic research in the physical sciences in the United States. Berkeley Lab’s Innovation and Partnerships Office, ipo.lbl.gov, connects industry partners with lab innovations, enabling lab-to-market transition.

Edma Fontaine,
ImaBiotech
Communication Manager
E: contact@imabiotech.com
T: +33 (0) 320 164 091